Drugs / Aroxxen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07397351 | Mar → Oct 2026 expected | coronary artery disorder | Research Institute of Geroprotective Technologies | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aroxxen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07397351 ↗ |
| Route | Inhaled | “administered by inhalation” NCT07397351 ↗ |